In recent years, the leukotriene modifiers, a new class of drugs, have become commercially available as a promising medication for asthma. According to the 1997 National Institutes of Health guidelines, the leukotriene modifiers are indicated in mild persistent asthma as an alternative to inhaled steroids. Nonetheless, they have been used in patients with moderate and severe asthma and, in some cases, they have made it possible for patients to taper or discontinue their use of oral steroids, thereby controlling their asthma while avoiding the side effects of oral corticosteroid. Since the introduction of zafirlukast, there have been reported at least eight cases of Churg-Strauss syndrome, a granulomatous, necrotizing vasculitis with eosinophilia, associated with the use of zafirlukast. No other leukotriene modifier has yet to be associated with the syndrome. All the patients in whom Churg-Strauss syndrome developed were patients with asthma who ere taking zafirlukast and were being weaned from oral corticosteroid. Reported here is a case of Churg-Strauss syndrome in a patient referred to the authors. Included is a review of the literature of the association of Churg-Strauss syndrome and zafirlukast therapy.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of the American Osteopathic Association|
|State||Published - May 1998|
All Science Journal Classification (ASJC) codes
- Complementary and alternative medicine